Alembic Pharmaceuticals Ltd today said it has entered into a joint venture with Orbicular Pharmaceutical Technologies and Dr MS Mohan to develop, manufacture and commercialise dermatology products for global markets.
“APL and Orbicular will own 60 per cent and 40 per cent of the equity capital of Aleor when the transaction is completed,” the Vadodara-based company said in a BSE filing.
It further said: “The joint venture agreement has standard terms including transfer of employees, financing and borrowing, management functioning, restriction on transfer of shares, non-compete, non-solicitation and termination events and consequences.”
Orbicular has capabilities in developing dermatology products with a fully-equipped and staff research laboratory in Hyderabad and has a pipeline of products under various stages of development, Alembic Pharma said.
Mohan is one of the founders of Orbicular Pharmaceutical Technologies.
“Manufacturing facility will be established in Aleor Dermaceuticals to enable worldwide registrations,” it added.
Shares of Alembic Pharmaceuticals shares were trading 6.75 per cent up at Rs 610 apiece on BSE.
More Like This
Published on April 21, 2016
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.